Small Pharma Stock Price, News & Analysis

DMTTF OTC

Company Description

Small Pharma Inc. (DMTTF) is a pharmaceutical company focused on developing novel treatments for mental health disorders. With a strong emphasis on research and innovation, Small Pharma aims to revolutionize the treatment landscape for conditions like depression, PTSD, and anxiety.

The company's cutting-edge pipeline includes proprietary compounds that have shown promising results in preclinical studies. Small Pharma's approach prioritizes patient-centered care and strives to address the unmet needs of individuals suffering from mental health issues.

Small Pharma has established strategic partnerships with leading research institutions and experts in the field of psychiatry, ensuring a comprehensive and rigorous approach to drug development. The company's dedication to scientific excellence and patient well-being sets it apart in the competitive pharmaceutical industry.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

- %

Performance 1 year

$37.5M

Market Cap

335.8M

Shares outstanding

Latest News

View All

October 23, 2023

0.00%

Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics

acquisition

October 19, 2023

9.70%

Small Pharma Reports Fiscal Second Quarter 2024 Highlights

earnings

October 17, 2023

0.00%

Small Pharma Obtains Final Order Approving Arrangement

October 12, 2023

7.43%

Small Pharma Announces Voting Results from Annual General and Special Meeting of Shareholders

September 26, 2023

5.56%

Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder

August 28, 2023

0.00%

Cybin to Acquire Small Pharma Inc.

acquisition

SEC Filings

View All

No SEC filings available for Small Pharma.

Financial Highlights

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Frequently Asked Questions

What is the market cap of Small Pharma (DMTTF)?

The market cap of Small Pharma (DMTTF) is approximately 37.5M.

What is Small Pharma Inc. focused on?

Small Pharma Inc. is focused on developing novel treatments for mental health disorders such as depression, PTSD, and anxiety.

What sets Small Pharma apart in the pharmaceutical industry?

Small Pharma is distinguished by its patient-centered approach, strategic partnerships with research institutions, and dedication to scientific excellence.

What is Small Pharma's pipeline like?

Small Pharma's pipeline includes proprietary compounds that have shown promising results in preclinical studies, offering hope for individuals with unmet mental health needs.

Who does Small Pharma collaborate with?

Small Pharma collaborates with leading research institutions and experts in psychiatry to ensure a comprehensive and rigorous approach to drug development.

What conditions does Small Pharma target?

Small Pharma targets mental health conditions such as depression, PTSD, and anxiety, aiming to revolutionize the treatment landscape for these disorders.

How does Small Pharma prioritize patient well-being?

Small Pharma prioritizes patient well-being by emphasizing patient-centered care in its drug development approach.

What results has Small Pharma achieved in preclinical studies?

Small Pharma's proprietary compounds have shown promising results in preclinical studies, demonstrating the potential for significant therapeutic benefits.

What is Small Pharma's mission?

Small Pharma's mission is to address the unmet needs of individuals suffering from mental health disorders by developing innovative and effective treatments.

Where can I find the latest news about Small Pharma Inc.?

Stay informed about the latest news and developments from Small Pharma Inc. by visiting their official website or following them on social media platforms.

How does Small Pharma contribute to the pharmaceutical industry?

Small Pharma contributes to the pharmaceutical industry by introducing novel approaches to mental health treatment and advancing scientific knowledge in the field of psychiatry.